RPL17P49: A Promising Drug Target / Biomarker (G100271388)

Target Name: RPL17P49

NCBI ID: G100271388

RPL17P49

Other Name(s): RPL17_20_1764 | ribosomal protein L17 pseudogene 49 | Ribosomal protein L17 pseudogene 49

RPL17P49: A Promising Drug Target / Biomarker

The protein RPL17P49 is a key regulator of the Replication Protein complex (RPC), which is responsible for copying DNA in eukaryotic cells. The RPL17P49 protein has been identified as a potential drug target and has been the focus of research in the field of molecular biology. In this article, we will explore the biology of RPL17P49 and its potential as a drug target.

Structure and Function

RPL17P49 is a 21 kDa protein that is expressed in most eukaryotic cells. It is a member of the RPL17 family of proteins, which are involved in the regulation of DNA replication. RPL17P49 is composed of a unique nucleotide-binding domain, a transmembrane region, and a cytoplasmic tail.

The nucleotide-binding domain is the region of the protein that interacts with DNA. It is composed of a nucleotide-binding oligomer that consists of a short oligonucleotide loop and a longer alpha-helical region. The nucleotide-binding domain is responsible for binding to the double-stranded DNA and initiating the replication process.

The transmembrane region is the region of the protein that spans the membrane of the eukaryotic cell. It is composed of a single transmembrane protein that contains a unique ATP-binding domain and a cytoplasmic tail. The ATP-binding domain is responsible for interacting with ATP and is involved in the regulation of the replication complex.

The cytoplasmic tail is the region of the protein that extends beyond the membrane of the eukaryotic cell. It is composed of a unique glycophorin that is involved in cell adhesion and signaling.

Drug Target Potential

The drug target potential of RPL17P49 is high due to its unique structure and function. RPL17P49 has been shown to play a critical role in the regulation of DNA replication, which is a crucial process for the survival of most eukaryotic cells. Therefore, targeting RPL17P49 with small molecules or antibodies may be an effective way to treat a variety of diseases.

One potential mechanism by which RPL17P49 can be targeted is through inhibition of its nucleotide-binding domain. The nucleotide-binding domain is responsible for binding to the double-stranded DNA and initiating the replication process. Therefore, inhibiting the activity of the nucleotide-binding domain can be an effective way to inhibit DNA replication.

Another potential mechanism by which RPL17P49 can be targeted is through inhibition of its cytoplasmic tail. The cytoplasmic tail is involved in cell adhesion and signaling, and therefore, inhibiting its activity may be an effective way to treat diseases that are characterized by cell signaling abnormalities.

Conclusion

In conclusion, RPL17P49 is a unique protein that plays a critical role in the regulation of DNA replication. Its nucleotide-binding domain, transmembrane region, and cytoplasmic tail make it an attractive target for small molecules and antibodies. Further research is needed to fully understand the biology of RPL17P49 and its potential as a drug target.

Protein Name: Ribosomal Protein L17 Pseudogene 49

The "RPL17P49 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL17P49 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets